Business Context and Reporting Period
Company: Penumbra, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 31, 2018
Event: Completion of an asset acquisition involving MVI Health Inc. ("MVI").
Key Financial Metrics
This filing reports a specific transaction rather than periodic financial performance. Key transaction metrics include:
- Cash Consideration Paid: $20.0 million paid to Sixense Enterprises, Inc. on the Closing Date.
- Ownership Stake Acquired: 40% of outstanding shares of MVI Health Inc.
- Post-Transaction Ownership: Penumbra's total interest in MVI increased from 50% to 90%.
- Contingent Consideration: An anti-dilution provision allows for the issuance of additional MVI shares to Sixense with an aggregate value up to $4.5 million.
Note: The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics for Penumbra, Inc. for the reporting period.
Material Changes
The primary material change is the increase in Penumbra's ownership of MVI Health Inc., a joint venture formed in May 2017 to explore healthcare applications of virtual reality technology. Prior to this transaction, Penumbra and Sixense each held a 50% interest. Following the acquisition of 40% of the outstanding shares from Sixense, Penumbra now holds a 90% interest.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the strategic intent to consolidate control over MVI's virtual reality healthcare initiatives. There is no forward-looking guidance or financial outlook provided in this specific report.
Risks and Contingencies:
- Contingent Liability: The agreement includes an anti-dilution provision potentially requiring the issuance of additional shares valued up to $4.5 million.
- Financial Reporting: Financial statements for the acquired business and pro forma financial information are not included in this filing. They may be filed by amendment within 71 days if required.
Investor Verification Checklist
- Verify the final ownership percentage of MVI Health Inc. held by Penumbra (stated as 90%).
- Monitor for the filing of MVI's financial statements and pro forma information within the 71-day window permitted by Item 9.01.
- Assess the potential impact of the $4.5 million contingent anti-dilution provision on future capital structure.
- Review subsequent filings for details on MVI's financial performance and integration progress.